Ferring Announces Ground-Breaking and Inclusive Family Building Benefits Package for All Its Employees Globally
14.7.2022 08:00:00 EEST | Business Wire | Press release
Ferring Pharmaceuticals is committed to building families of every shape and size. As part of this commitment, Ferring has announced the introduction of a new global family building benefits package for its employees. The holistic three-tier support model provides family building financial benefits, a ground-breaking 26-week global minimum standard of equal paid parental leave for both birthing and non-birthing parents as well as increased awareness and support at work.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220707005467/en/
(Infographic: Business Wire)
The comprehensive package recognises the complexities of building a family and aims to enable different family building options by removing the financial barriers and providing access to quality care. Unlimited financial assistance is provided within the scope of its providers’ services.
Ferring’s support package provides equal opportunities to becoming a parent regardless of medical need, personal circumstances or family structure. This means providing the financial support required to access fertility treatments, surrogacy programmes, adoption, egg freezing, counselling and related services. Additionally, to ensure employees feel supported during the process of their family building journey, paid leave is available for fertility treatment and adoption procedures.
Building on the long-standing fertility benefits package offered to its US-based employees via its provider, Progyny, Ferring has now engaged Carrot, to support its employees in the rest of the world.
Infertility is a significant clinical issue, estimated to affect 1 in 6 heterosexual couples globally.1,2 Research has found that the negative impacts of infertility are profound and a clear gap exists between the number of people who experience mental health issues due to infertility and the number seeking help to address these mental health issues.3 Underlying the practical support provided by the new package will be support for employees’ emotional wellbeing, with four weeks paid leave provided for miscarriage for example, and counselling services offered to all employees from the outset of their fertility journey.
“At Ferring we commit to advocating for everyone’s right to build a family, no matter who you are, where you live or who you love. The new family building support package ensures a global standard for support irrespective of location, role or family circumstances. It makes no assumptions about gender, sexual orientation or relationship status, or about parental roles or responsibilities in the early stages of childcare,” said Christelle Beneteau, Executive Committee member and Chief Human Resources Officer at Ferring Pharmaceuticals.
Christelle added: “As we strive to lead by example in becoming a fertility and family friendly employer, I’m immensely proud of this world-leading, comprehensive and inclusive package. All of our employees collectively contribute to advancing our mission to build families and help people live better lives. We want to do everything we can to support them in their own family building journeys, removing barriers and provide an environment in which they are empowered to focus on their families at this important time.”
As a leading global healthcare company in reproductive medicine and maternal health, Ferring aims to advance its #ProjectFamily Commitment by creating a fertility and family friendly experience at work and increase awareness of the experiences of family building journeys and to foster support, respect and understanding in all its workplaces. Through training, awareness events and open dialogue, Ferring will ensure that its new family building support package goes further than financial assistance or leave policies and creates a world leading family and fertility friendly workplace.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs around 6,000 people worldwide, has its own operating subsidiaries in more than 50 countries, and markets its products in 110 countries.
Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.
Note: The availability of financial support and access to some benefits is subject to compliance with local laws.
# # #
References:
1 European Society of Human Reproduction and Embryology, ART Factsheet 2018. Available at: https://www.eshre.eu/Press-Room/Resources. Last accessed March 2022.
2 World Health Organization. Infertility. Available https://www.who.int/health-topics/infertility#tab=tab_1. Last accessed March 2022.
3 Boivin J et al. Tailored support may be required to reduce the impact of the infertility journey on mental health, relationships and daily lives of infertile patients and partners to infertile patients. Reproductive Biomedicine online. March 2022. DOI: https://doi.org/10.1016/j.rbmo.2022.01.015
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220707005467/en/
Contact information
For more information, please contact
Yasmin Gharib
Account Director, Syneos Health Communications PR Europe
+44 (0)7788 663 999 (mobile)
yasmin.gharib@syneoshealth.com
A
dam Alexander
Senior Account Executive, Syneos Health Communications PR Europe
+44 785 469 4245 (mobile)
adam.alexander@syneoshealth.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Present New Data on ALYFTREK ® at the North American Cystic Fibrosis Conference9.10.2026 20:15:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine pancreatic function represent a profound shift in how we understand the benefits of treating cystic fibrosis in its earliest stages,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Devel
Verdant Rock Receives A (low) Financial Strength Rating from Morningstar DBRS, Adding a Second International Investment-Grade Assessment9.10.2026 17:00:00 EEST | Press release
Verdant Rock Limited, a Bermuda Monetary Authority-regulated Class 3B insurance company, has received an A (low) Financial Strength Rating from Morningstar DBRS. The rating reflects Verdant Rock’s financial strength and its capacity to meet policyholder obligations as an investment-grade financial guarantor for Emerging Markets credit. Morningstar DBRS is a global credit rating agency with coverage across North America, Europe, Asia, and Latin America. Its assessment of Verdant Rock reflects the company’s strong projected earnings ability, robust risk profile, sound liquidity, and good capitalization. Morningstar DBRS also assigned an A (low) Issuer Rating to Verdant Rock. The rating follows Verdant Rock’s BBB+ Long-Term Insurer Financial Strength Rating with a Stable Outlook from Fitch Ratings, assigned on 12 June 2026. Verdant Rock now holds Financial Strength Ratings from both Fitch Ratings and Morningstar DBRS, providing counterparties with dual-agency confirmation of the company’s
Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions9.10.2026 16:17:00 EEST | Press release
Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced that Gartner has positioned it as a Visionary in the first-ever Magic Quadrant for AI-Enabled CSP Marketing and Sales Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009905430/en/ Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions A new category for a new operating model. CSPs are fighting saturated markets, rising acquisition costs, and accelerating churn. They are responding with AI-driven automation across the full revenue cycle, from segmentation and campaigns to lead management, CPQ, and renewals, increasingly executed by autonomous agents. According to us, Gartner creation of this Magic Quadrant confirms the shift has moved from pilot to boardroom priority. According to Gartner, Visionaries "understands where the market
Positive New Data on Corcym’s Perceval Plus Sutureless Aortic Heart Valve Encompasses up to 7-Year Follow-up9.10.2026 16:15:00 EEST | Press release
Corcym, a global medical device company dedicated to cardiac surgery, today announced that positive mid-term data from a sub-analysis of its Perceval Plus sutureless aortic heart valve as part of its MANTRA clinical trial was featured in an oral presentation today at the annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS). The study is the longest follow-up available for Perceval Plus and the FREE tissue treatment from an international multicenter study, and demonstrated excellent durability, safety and quality of life improvements. Perceval Plus is the only sutureless and collapsible aortic surgical heart valve. Its unique design performs in any surgical scenario and is optimal for endoscopy and robotics. The valve features the company’s FREE next generation tissue treatment addressing the two main causes of calcification, phospholipids and aldehydes. Its proprietary LANCELOT advanced manufacturing process includes zero-pressure shaping and laser cutting of
Ada earns AWS Travel and Hospitality Competency for resolving traveler issues at scale9.10.2026 16:00:00 EEST | Press release
Ada, the pioneer in Agentic Customer Experience, today announced it has achieved the Amazon Web Services (AWS) Travel and Hospitality Competency. The designation recognizes Ada as an AWS Partner with demonstrated technical proficiency and proven customer success helping travel and hospitality brands resolve customer issues at scale. Ada joins a select group of 58 AWS Partners holding the competency, and it reflects a shared commitment to helping travel brands deliver service that holds up on their busiest, most unpredictable days. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009673638/en/ Ada earns AWS Travel and Hospitality Competency for resolving traveler issues at scale "Travel is where agentic customer service gets tested hardest. Demand spikes without warning, policies change by the hour, and customers are often stressed and far from home," said Mike Murchison, CEO and co-founder of Ada. "Our airline and hospitali
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
